Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Journey Medical
DERM
Market cap
$189M
Overview
Fund Trends
Analyst Outlook
Journalist POV
7.20
USD
--0.20
2.7%
At close
Updated
Oct 17, 4:00 PM EDT
Pre-market
After hours
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-2.7%
5 days
-1.5%
1 month
2.13%
3 months
-1.37%
6 months
15.2%
Year to date
80%
1 year
20.6%
5 years
-24.21%
10 years
-24.21%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
61.5%
Negative
Positive
Neutral
Negative
Neutral
GlobeNewsWire
10 days ago
Journey Medical Corporation to Participate in October 2025 Investor Conferences
SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in two October 2025 investor conferences.
Positive
Seeking Alpha
1 month ago
Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon
EMROSI's strong launch is driving Journey Medical's growth, with rapid prescription uptake, expanding prescriber base, and improved payer coverage fueling margin expansion. I see EMROSI as the primary value driver, positioning DERM for sustainable EBITDA profitability by year-end and strong long-term revenue and EPS growth potential. Key risks include Accutane's generic erosion, uncertainty in EMROSI's net revenue per script, and limited cash reserves that may require future capital raises.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for September 4th
DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation to Participate in September 2025 Investor Conferences
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation to Present at the Emerging Growth Conference
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.
Negative
Benzinga
2 months ago
CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.
Neutral
Seeking Alpha
2 months ago
Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Mayank Mamtani - B.
Neutral
Zacks Investment Research
2 months ago
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.
Positive
Zacks Investment Research
2 months ago
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close